CLINICAL AND ECONOMIC ANALYSIS OF ETANERCEPT EFFICACY IN A PATIENT WITH JUVENILE HEUMATOID ARTHRITIS

Abstract

Article contains clinical and economic analysis of treatment efficacy of a patient with a poliarticular form of juvenile rheumatoid arthritis (JRA) with soluble TNF receptors — etanercept. Such methods of analysis as «disease value» and «expense–efficacy» were used. It has been shown that «disease value» increases against the background of etarnecept use. However, further analysis has shown that from the «expense–efficacy» point etarnecept use decreases expenses in 6.3 times (both direct and indirect expenses, in 4.3 times using only direct expenses) in comparison to standard antirheumatic treatment, that lays economic grounds for etarnecept use for patients with refractory JRA.

Keywords

• juvenile rheumatoid arthritis
• clinical and economic analysis
• disease value
• etarnecept